SAN DIEGO, April 09, 2018 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq:KURA), a clinical-stage biopharmaceutical company focused on the development of precision medicines for oncology, today announced that three abstracts relating to the company’s lead product candidate, tipifarnib, and ERK inhibitor, KO-947, will be presented at the upcoming American Association for Cancer Research (AACR) Annual Meeting 2018, which will be held from April 14-18, 2018 in Chicago. The following abstracts are now available on the AACR website at www.aacr.org.
Tipifarnib is Highly Active in HRAS Mutant Lung Squamous Carcinoma Tumor
Models (Abstract # 4917)
Session Category: Experimental and Molecular Therapeutics
Session Title: Pharmacokinetics and Pharmacodynamics
Session Date and Time: Tuesday, April 17, 2018, 1:00 p.m. - 5:00 p.m.
Location: McCormick Place South, Exhibit Hall A, Poster Section 41
11q13 Amplification Selects for Sensitivity to the ERK Inhibitor KO-947 in
Squamous Cell Carcinomas (Abstract # 3885)
Session Category: Experimental and Molecular Therapeutics
Session Title: Pharmacogenetics and Pharmacogenomics
Session Date and Time: Tuesday, April 17, 2018, 8:00 a.m. - 12:00 p.m.
Location: McCormick Place South, Exhibit Hall A, Poster Section 37
Preclinical Activity of Tipifarnib in Cutaneous T-cell Lymphoma (Abstract # 1873)
Session Category: Experimental and Molecular Therapeutics
Session Title: Experimental Agents and Combinations for Hematologic Malignancies 2
Session Date and Time: Monday, April 16, 2018, 8:00 a.m. - 12:00 p.m.
Location: McCormick Place South, Exhibit Hall A, Poster Section 38
Following presentation at the meeting, the posters will be available on Kura's website at www.kuraoncology.com.
About Kura Oncology
Kura Oncology is a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer. The company’s pipeline consists of small molecule drug candidates that target cancer signaling pathways where there is a strong scientific and clinical rationale to improve outcomes by identifying those patients most likely to benefit from treatment. Kura Oncology’s lead drug candidate is tipifarnib, a farnesyl transferase inhibitor, which is currently being studied in multiple Phase 2 clinical trials in solid tumor and hematologic indications. The company plans to initiate the AIM-HN trial, a single-arm, registration-directed trial of tipifarnib in at least 59 recurrent or metastatic patients with HRAS mutant squamous cell head and neck cancer (HNSCC) in the second half of 2018. Kura’s pipeline also includes KO-947, an ERK inhibitor, currently in a Phase 1 trial, and KO-539, an inhibitor of the menin-MLL protein-protein interaction, currently in preclinical development. For additional information about Kura Oncology, please visit the company’s website at www.kuraoncology.com.
Forward-Looking Statements
This news release contains certain forward-looking statements that involve risks and uncertainties that could cause actual results to be materially different from historical results or from any future results expressed or implied by such forward-looking statements. Such forward-looking statements include statements regarding, among other things, the efficacy, safety and therapeutic potential of the company’s product candidates, progress and expected timing of Kura Oncology’s drug development programs and clinical trials and plans regarding future clinical trials and development activities. Factors that may cause actual results to differ materially include the risk that compounds that appeared promising in early research or clinical trials do not demonstrate safety and/or efficacy in later preclinical studies or clinical trials, the risk that Kura Oncology may not obtain approval to market its product candidates, uncertainties associated with performing clinical trials, regulatory filings and applications, risks associated with reliance on third parties to successfully conduct clinical trials, the risks associated with reliance on outside financing to meet capital requirements, and other risks associated with the process of discovering, developing and commercializing drugs that are safe and effective for use as human therapeutics, and in the endeavor of building a business around such drugs. You are urged to consider statements that include the words "may," "will," "would," "could," "should," "believes," "estimates," "projects," "promise, " "potential," "expects," "plans," "anticipated," "intends," "continues," "designed," "goal," or the negative of those words or other comparable words to be uncertain and forward-looking. For a further list and description of the risks and uncertainties the company faces, please refer to the company's periodic and other filings with the Securities and Exchange Commission, which are available at www.sec.gov. Such forward-looking statements are current only as of the date they are made, and Kura Oncology assumes no obligation to update any forward-looking statements, whether as a result of new information, future events or otherwise.
Contacts
Company:
Pete De Spain
Vice President, Investor Relations &
Corporate Communications
(858) 500-8803
pete@kuraoncology.com
Investors:
Robert H. Uhl
Managing Director
Westwicke Partners, LLC
(858) 356-5932
robert.uhl@westwicke.com
Media:
Jason Spark
Managing Director
Canale Communications
(619) 849-6005
jason@canalecomm.com